리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 01월
페이지 정보:영문 179 Pages
라이선스 & 가격 (부가세 별도)
한글목차
압타머 세계 시장은 2030년까지 4억 7,790만 달러에 달할 전망
2024년에 1억 9,960만 달러로 추정되는 앱타머 세계 시장은 2030년에는 4억 7,790만 달러에 달할 것으로 예상되며, 분석 기간인 2024-2030년 동안 15.7%의 CAGR로 성장할 것으로 예상됩니다. 본 보고서에서 분석하는 부문 중 하나인 DNA 앱타머는 CAGR 15.7%을 기록하여 분석 기간 종료 시점에 2억 2,750만 달러에 도달할 것으로 예상되며, XNA 앱타머 부문의 성장률은 분석 기간 동안 CAGR 16.1%로 추정됩니다.
미국 시장 5,300만 달러로 추정, 중국은 CAGR 21.0%로 성장 전망
미국의 압타머 시장은 2024년 5,300만 달러로 추정됩니다. 세계 2위의 경제 대국인 중국은 2030년까지 1억 1,510만 달러의 시장 규모에 도달할 것으로 예상되며, 분석 기간인 2024-2030년 동안 CAGR은 21.0%에 달할 것으로 예상됩니다. 다른 주목할 만한 지역 시장으로는 일본과 캐나다가 있으며, 분석 기간 동안 각각 11.3%와 13.0%의 CAGR을 기록할 것으로 예상됩니다. 유럽에서는 독일이 CAGR 약 12.2% 성장할 것으로 예상됩니다.
세계 압타머 시장 - 주요 동향 및 촉진요인 정리
왜 압타머는 현대 생명공학에서 추진력을 얻고 있는가?
앱타머, DNA, RNA, 펩타이드 분자의 짧은 사슬은 현대 생명공학의 강력한 도구로 등장하여 기존의 항체를 대체할 수 있는 유망한 대안으로 떠오르고 있습니다. 이 분자들은 높은 친화력과 특이성으로 특정 표적에 결합할 수 있어 치료, 진단, 연구를 포함한 광범위한 응용 분야에 이상적입니다. 압타머가 특히 매력적인 이유는 화학적으로 합성할 수 있기 때문에 생물학적 제조 방법을 필요로 하는 항체와 달리 높은 재현성과 배치 일관성을 얻을 수 있다는 점입니다. 또한, 앱타머는 안정성, 반감기, 표적 특이성을 향상시키기 위해 쉽게 변형할 수 있어 다양한 환경에서 활용도가 높습니다. 압타머는 독특한 3차원 구조로 접을 수 있기 때문에 저분자에서 거대 단백질까지 다양한 표적을 인식할 수 있으며, 같은 단백질의 다른 아이소폼을 식별할 수도 있습니다. 생명공학의 발전에 따라 새로운 진단 도구, 표적 치료제, 바이오센서 개발에서 압타머의 중요성이 점점 더 커지고 있습니다.
기술의 발전은 압타머의 미래를 어떻게 형성하고 있을까?
압타머의 미래는 압타머의 능력과 응용을 확대하는 기술의 발전에 크게 영향을 받고 있으며, SELEX(Systematic Evolution of Ligands by Exponential Enrichment) 기술의 개발은 압타머 연구에서 매우 중요하며, 표적에 대한 높은 특이성과 친밀도를 가진 압타머를 신속하고 효율적으로 선택할 수 있게 해줍니다. 에 대해 높은 특이성과 친화력을 가진 압타머를 신속하고 효율적으로 선택할 수 있게 되었습니다. 최근 SELEX의 개선으로 점점 더 복잡한 표적에 대한 압타머의 식별이 가능해져 잠재적인 응용 범위가 넓어지고 있습니다. 또한, 화학적 합성 및 변형 기술의 발전으로 고온 및 효소 분해와 같은 가혹한 조건에서도 견딜 수 있는 보다 안정적이고 견고한 압타머의 생산이 가능해졌습니다. 따라서 생체 내 치료 응용이나 산업 공정과 같은 까다로운 환경에서 특히 유용하게 사용되고 있습니다. 또한, 압타머를 나노기술과 융합함으로써 표적 약물전달의 새로운 가능성을 열어주었습니다. 압타머를 사용하면 치료제를 질병 세포에 직접 유도하여 부작용을 최소화하고 치료 효과를 향상시킬 수 있습니다. 이러한 기술 혁신은 앱타머의 성능을 향상시킬 뿐만 아니라, 보다 광범위한 산업 분야로의 채택을 촉진하고 있습니다.
헬스케어 분야에서 앱타머의 도입을 촉진하는 새로운 트렌드는 무엇일까?
몇 가지 주요 트렌드가 헬스케어 분야에서 앱타머의 채택 확대를 촉진하고 있으며, 이는 업계에서 앱타머의 중요성이 커지고 있음을 보여줍니다. 가장 중요한 트렌드 중 하나는 맞춤형 의료에 대한 수요 증가입니다. 맞춤의료란 유전적 체질이나 특정 질병 특성에 따라 환자 개개인에 맞는 치료를 하는 것을 말합니다. 앱타머는 정확한 타겟에 맞게 설계할 수 있기 때문에 맞춤치료 개발에 중요한 역할을 하고 있습니다. 또 다른 중요한 트렌드는 압타머를 이용한 진단법의 확대입니다. 이러한 진단법은 질병의 조기 발견부터 치료 효과 모니터링에 이르기까지 다양한 용도로 사용되고 있으며, 기존 진단법을 대체할 수 있는 보다 침습적이지 않으면서도 정확한 진단법을 제공하고 있습니다. 또한, 단클론항체보다 경제적으로 제조할 수 있어 치료와 진단 양면에서 비용 효율적인 솔루션을 제공할 수 있어 헬스케어 비용 절감에 대한 관심이 높아지면서 앱타머에 대한 관심이 높아지고 있습니다. 이러한 추세는 앱타머가 주류 의료에 통합되는 것을 가속화하고 있으며, 앱타머를 미래 의료 혁신의 핵심 요소로 만들고 있습니다.
압타머 시장의 성장을 촉진하는 요인은 무엇일까?
압타머 시장의 성장은 기술 발전, 진화하는 헬스케어 수요, 업계 동향과 밀접하게 연관된 몇 가지 요인에 의해 주도되고 있습니다. 첫째, 생명공학 연구, 특히 신약 연구개발 분야에 대한 투자 증가는 새로운 치료 표적을 발굴할 수 있는 유연하고 효율적인 플랫폼을 제공하기 때문에 앱타머에 대한 수요를 증가시키고 있습니다. 둘째, 보다 정확하고 조기 발견이 필요한 질병 진단에 앱타머의 적용 확대가 시장 성장에 크게 기여하고 있습니다. 앱타머는 환자 개개인에 맞는 표적 치료의 수요를 충족시킬 수 있는 독보적인 위치에 있기 때문에 맞춤형 의료의 부상도 큰 원동력이 되고 있습니다. 또한, 만성질환과 암의 유병률 증가는 혁신적인 치료 및 진단 도구에 대한 강력한 수요를 창출하여 앱타머의 채택을 더욱 촉진하고 있습니다. 또한, 점점 더 많은 앱타머 기반 제품들이 임상 승인을 받으면서 이 분야에 대한 투자와 개발이 더욱 활발히 이루어지고 있는 등 규제 환경이 개선되고 있습니다. 이러한 요인들은 지속적인 기술 혁신과 함께 압타머 시장의 급속한 확장을 촉진하고 있으며, 압타머는 생명공학 및 헬스케어의 미래에 중요한 역할을 할 수 있는 중요한 요소로 자리매김하고 있습니다.
부문
유형(DNA 앱타머, XNA 앱타머, RNA 앱타머), 기술(SELEX, 기타 기술), 용도(치료제 개발, 연구개발, 진단약, 기타 용도), 최종 용도(제약/바이오 기업, 학계/정부 연구기관, 기타 최종 용도)
조사 대상 기업 예시(총 12개사)
AM Biotechnologies, LLC
Aptagen, LLC
Aptamer Group
Aptamer Sciences Inc.
Aptus Biotech
Base Pair Biotechnologies, Inc.
NeoVentures Biotechnology Inc.
SomaLogic, Inc.
TriLink BioTechnologies, LLC.
Vivonics, Inc.
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 성장 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSM
영문 목차
영문목차
Global Aptamers Market to Reach US$477.9 Million by 2030
The global market for Aptamers estimated at US$199.6 Million in the year 2024, is expected to reach US$477.9 Million by 2030, growing at a CAGR of 15.7% over the analysis period 2024-2030. DNA Aptamers, one of the segments analyzed in the report, is expected to record a 15.7% CAGR and reach US$227.5 Million by the end of the analysis period. Growth in the XNA Aptamers segment is estimated at 16.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$53.0 Million While China is Forecast to Grow at 21.0% CAGR
The Aptamers market in the U.S. is estimated at US$53.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$115.1 Million by the year 2030 trailing a CAGR of 21.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.3% and 13.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.2% CAGR.
Global Aptamers Market - Key Trends and Drivers Summarized
Why Are Aptamers Gaining Momentum in Modern Biotechnology?
Aptamers, short strands of DNA, RNA, or peptide molecules, have emerged as a powerful tool in modern biotechnology, offering a promising alternative to traditional antibodies. These molecules can bind to specific targets with high affinity and specificity, making them ideal for a wide range of applications, including therapeutics, diagnostics, and research. Aptamers are particularly attractive because they can be synthesized chemically, allowing for high reproducibility and batch consistency, unlike antibodies that require biological production methods. Furthermore, aptamers can be easily modified to improve their stability, half-life, and target specificity, making them highly versatile in different environments. Their ability to fold into unique three-dimensional structures enables them to recognize a diverse array of targets, from small molecules to large proteins, even distinguishing between different isoforms of the same protein. As biotechnology continues to advance, aptamers are becoming increasingly important in developing new diagnostic tools, targeted therapies, and biosensors, reflecting their growing significance in the field.
How Are Technological Advancements Shaping the Future of Aptamers?
The future of aptamers is being profoundly influenced by technological advancements that are expanding their capabilities and applications. The development of Systematic Evolution of Ligands by Exponential Enrichment (SELEX) technology has been pivotal in aptamer research, allowing for the rapid and efficient selection of aptamers with high specificity and affinity for their targets. Recent improvements in SELEX have made it possible to identify aptamers for increasingly complex targets, broadening the scope of potential applications. Additionally, advancements in chemical synthesis and modification techniques have enabled the production of more stable and robust aptamers, which can withstand harsh conditions such as high temperatures and enzymatic degradation. This has made them particularly useful in challenging environments like in vivo therapeutic applications and industrial processes. Moreover, the integration of aptamers with nanotechnology has opened up new possibilities for targeted drug delivery, where aptamers are used to guide therapeutic agents directly to diseased cells, minimizing side effects and improving treatment efficacy. These technological innovations are not only enhancing the performance of aptamers but also driving their adoption in a wider array of industries.
What Emerging Trends Are Driving the Adoption of Aptamers in Healthcare?
Several key trends are driving the increasing adoption of aptamers in healthcare, highlighting their growing relevance in the industry. One of the most significant trends is the rising demand for personalized medicine, where treatments are tailored to individual patients based on their genetic makeup and specific disease characteristics. Aptamers, with their ability to be designed for precise targets, are playing a crucial role in the development of personalized therapies, particularly in oncology where they can be used to deliver drugs directly to cancer cells while sparing healthy tissues. Another important trend is the expansion of aptamer-based diagnostics, which are becoming increasingly popular due to their sensitivity and specificity. These diagnostics are being used in a wide range of applications, from early disease detection to monitoring therapeutic efficacy, offering a less invasive and more accurate alternative to traditional diagnostic methods. Additionally, the growing focus on reducing healthcare costs is leading to greater interest in aptamers, as they can be produced more economically than monoclonal antibodies, offering a cost-effective solution for both therapeutic and diagnostic purposes. These trends are accelerating the integration of aptamers into mainstream healthcare, making them a key component of future medical innovations.
What Factors Are Driving Growth in the Aptamer Market?
The growth in the aptamer market is driven by several factors that are closely tied to advancements in technology, evolving healthcare needs, and industry trends. Firstly, the increasing investment in biotechnology research, particularly in the fields of drug discovery and development, is boosting the demand for aptamers as they provide a flexible and efficient platform for identifying new therapeutic targets. Secondly, the expanding application of aptamers in diagnostics, driven by the need for more precise and early detection of diseases, is significantly contributing to market growth. The rise of personalized medicine is also a major driver, as aptamers are uniquely positioned to meet the demand for targeted therapies that can be tailored to individual patients. Additionally, the growing prevalence of chronic diseases and cancer is creating a strong demand for innovative treatments and diagnostic tools, further fueling the adoption of aptamers. Moreover, the regulatory landscape is becoming increasingly favorable, with more aptamer-based products receiving approvals for clinical use, which is encouraging further investment and development in this field. These factors, combined with ongoing technological innovations, are propelling the rapid expansion of the aptamer market, positioning it as a key player in the future of biotechnology and healthcare.
SCOPE OF STUDY:
The report analyzes the Aptamers market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Type (DNA Aptamers, XNA Aptamers, RNA Aptamers); Technology (SELEX, Other Technologies); Application (Therapeutics Development, Research & Development, Diagnostics, Other Applications); End-Use (Pharma & Biotech Companies, Academic & Government Research Institutes, Other End-Uses)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 12 Featured) -
AM Biotechnologies, LLC
Aptagen, LLC
Aptamer Group
Aptamer Sciences Inc.
Aptus Biotech
Base Pair Biotechnologies, Inc.
NeoVentures Biotechnology Inc.
SomaLogic, Inc.
TriLink BioTechnologies, LLC.
Vivonics, Inc.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Aptamers - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
Global Economic Update
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Growing Interest in Precision Medicine Spurs Growth in Aptamer-Based Therapeutics
Advancements in SELEX Technology Strengthen the Business Case for Aptamer Development
Rising Demand for Targeted Drug Delivery Expands Addressable Market for Aptamers
Innovations in Diagnostic Applications Propel Growth in Aptamer-Based Assays
Growing Application of Aptamers in Biosensors Spurs Demand in Diagnostic Markets
Emerging Use of Aptamers in Oncology Generates New Market Opportunities
Expansion of Nanotechnology Applications in Medicine Expands Opportunities for Aptamers
Rising Demand for Non-Immunogenic Therapeutics Spurs Growth in Aptamer Market
Growing Use of Aptamers in Agricultural Biotechnology Generates New Market Niches
Focus on Early Disease Detection Expands the Market for Aptamer-Based Diagnostics
Advancements in RNA Aptamers Propel Growth in Research and Therapeutic Applications
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for SELEX by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 2: World 6-Year Perspective for SELEX by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 3: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 4: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 6: World 6-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 8: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 9: World Recent Past, Current & Future Analysis for DNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 10: World 6-Year Perspective for DNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for XNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 12: World 6-Year Perspective for XNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 13: World Recent Past, Current & Future Analysis for RNA Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 14: World 6-Year Perspective for RNA Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 15: World Recent Past, Current & Future Analysis for Therapeutics Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 16: World 6-Year Perspective for Therapeutics Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Research & Development by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 18: World 6-Year Perspective for Research & Development by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 20: World 6-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 21: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 22: World 6-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Academic & Government Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 24: World 6-Year Perspective for Academic & Government Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
TABLE 25: World Aptamers Market Analysis of Annual Sales in US$ for Years 2015 through 2030
TABLE 26: World Recent Past, Current & Future Analysis for Aptamers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 27: World 6-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 28: USA Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 29: USA 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 30: USA Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 31: USA 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 32: USA Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 33: USA 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 34: USA Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 35: USA 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
CANADA
TABLE 36: Canada Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 37: Canada 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 38: Canada Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 39: Canada 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 40: Canada Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 41: Canada 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 42: Canada Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 43: Canada 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
JAPAN
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 44: Japan Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 45: Japan 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 46: Japan Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 47: Japan 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 48: Japan Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 49: Japan 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 50: Japan Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 51: Japan 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
CHINA
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 52: China Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 53: China 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 54: China Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 55: China 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 56: China Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 57: China 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 58: China Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 59: China 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
EUROPE
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 60: Europe Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 61: Europe 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 62: Europe Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 63: Europe 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 64: Europe Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 65: Europe 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 66: Europe Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 67: Europe 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
TABLE 68: Europe Recent Past, Current & Future Analysis for Aptamers by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 69: Europe 6-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
FRANCE
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 70: France Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 71: France 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 72: France Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 73: France 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 74: France Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 75: France 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 76: France Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 77: France 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
GERMANY
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 78: Germany Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 79: Germany 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 80: Germany Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 81: Germany 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 82: Germany Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 83: Germany 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 84: Germany Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 85: Germany 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
ITALY
TABLE 86: Italy Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 87: Italy 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 88: Italy Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 89: Italy 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 90: Italy Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 91: Italy 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 92: Italy Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 93: Italy 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
UNITED KINGDOM
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 94: UK Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 95: UK 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 96: UK Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 97: UK 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 98: UK Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 99: UK 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 100: UK Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 101: UK 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
SPAIN
TABLE 102: Spain Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 103: Spain 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 104: Spain Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 105: Spain 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 106: Spain Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 107: Spain 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 108: Spain Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 109: Spain 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
RUSSIA
TABLE 110: Russia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 111: Russia 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 112: Russia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 113: Russia 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 114: Russia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 115: Russia 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 116: Russia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 117: Russia 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
REST OF EUROPE
TABLE 118: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 119: Rest of Europe 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 120: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 121: Rest of Europe 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 122: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 123: Rest of Europe 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 124: Rest of Europe Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 125: Rest of Europe 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
ASIA-PACIFIC
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 126: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 127: Asia-Pacific 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 128: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 129: Asia-Pacific 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 130: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 131: Asia-Pacific 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 132: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 133: Asia-Pacific 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
TABLE 134: Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 135: Asia-Pacific 6-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
AUSTRALIA
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 136: Australia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 137: Australia 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 138: Australia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 139: Australia 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 140: Australia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 141: Australia 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 142: Australia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 143: Australia 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
INDIA
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 144: India Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 145: India 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 146: India Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 147: India 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 148: India Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 149: India 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 150: India Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 151: India 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
SOUTH KOREA
TABLE 152: South Korea Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 153: South Korea 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 154: South Korea Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 155: South Korea 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 156: South Korea Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 157: South Korea 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 158: South Korea Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 159: South Korea 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 160: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 161: Rest of Asia-Pacific 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 162: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 163: Rest of Asia-Pacific 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 164: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 165: Rest of Asia-Pacific 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 166: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 167: Rest of Asia-Pacific 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
LATIN AMERICA
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 168: Latin America Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 169: Latin America 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 170: Latin America Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 171: Latin America 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 172: Latin America Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 173: Latin America 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 174: Latin America Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 175: Latin America 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
TABLE 176: Latin America Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 177: Latin America 6-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
ARGENTINA
TABLE 178: Argentina Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 179: Argentina 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 180: Argentina Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 181: Argentina 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 182: Argentina Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 183: Argentina 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 184: Argentina Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 185: Argentina 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
BRAZIL
TABLE 186: Brazil Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 187: Brazil 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 188: Brazil Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 189: Brazil 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 190: Brazil Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 191: Brazil 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 192: Brazil Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 193: Brazil 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
MEXICO
TABLE 194: Mexico Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 195: Mexico 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 196: Mexico Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 197: Mexico 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 198: Mexico Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 199: Mexico 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 200: Mexico Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 201: Mexico 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
REST OF LATIN AMERICA
TABLE 202: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 203: Rest of Latin America 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 204: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 205: Rest of Latin America 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 206: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 207: Rest of Latin America 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 208: Rest of Latin America Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 209: Rest of Latin America 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
MIDDLE EAST
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 210: Middle East Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 211: Middle East 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 212: Middle East Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 213: Middle East 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 214: Middle East Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 215: Middle East 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 216: Middle East Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 217: Middle East 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
TABLE 218: Middle East Recent Past, Current & Future Analysis for Aptamers by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
TABLE 219: Middle East 6-Year Perspective for Aptamers by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
IRAN
TABLE 220: Iran Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 221: Iran 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 222: Iran Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 223: Iran 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 224: Iran Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 225: Iran 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 226: Iran Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 227: Iran 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
ISRAEL
TABLE 228: Israel Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 229: Israel 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 230: Israel Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 231: Israel 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 232: Israel Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 233: Israel 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 234: Israel Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 235: Israel 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
SAUDI ARABIA
TABLE 236: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 237: Saudi Arabia 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 238: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 239: Saudi Arabia 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 240: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 241: Saudi Arabia 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 242: Saudi Arabia Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 243: Saudi Arabia 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
UNITED ARAB EMIRATES
TABLE 244: UAE Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 245: UAE 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 246: UAE Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 247: UAE 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 248: UAE Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 249: UAE 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 250: UAE Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 251: UAE 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
REST OF MIDDLE EAST
TABLE 252: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 253: Rest of Middle East 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 254: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 255: Rest of Middle East 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 256: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 257: Rest of Middle East 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 258: Rest of Middle East Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 259: Rest of Middle East 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030
AFRICA
Aptamers Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 260: Africa Recent Past, Current & Future Analysis for Aptamers by Type - DNA Aptamers, XNA Aptamers and RNA Aptamers - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 261: Africa 6-Year Perspective for Aptamers by Type - Percentage Breakdown of Value Sales for DNA Aptamers, XNA Aptamers and RNA Aptamers for the Years 2025 & 2030
TABLE 262: Africa Recent Past, Current & Future Analysis for Aptamers by Technology - SELEX and Other Technologies - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 263: Africa 6-Year Perspective for Aptamers by Technology - Percentage Breakdown of Value Sales for SELEX and Other Technologies for the Years 2025 & 2030
TABLE 264: Africa Recent Past, Current & Future Analysis for Aptamers by Application - Therapeutics Development, Research & Development, Diagnostics and Other Applications - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 265: Africa 6-Year Perspective for Aptamers by Application - Percentage Breakdown of Value Sales for Therapeutics Development, Research & Development, Diagnostics and Other Applications for the Years 2025 & 2030
TABLE 266: Africa Recent Past, Current & Future Analysis for Aptamers by End-Use - Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
TABLE 267: Africa 6-Year Perspective for Aptamers by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Academic & Government Research Institutes and Other End-Uses for the Years 2025 & 2030